EEF1A2 eukaryotic translation elongation factor 1 alpha 2
ENSG00000101210 · protein coding · Open Targets profile
Translation elongation factor that catalyzes the GTP- dependent binding of aminoacyl-tRNA (aa-tRNA) to the A-site of ribosomes during the elongation phase of protein synthesis. Base pairing between the mRNA codon and the aa-tRNA anticodon promotes GTP hydrolysis, releasing the aa-tRNA from EEF1A1 and allowing its accommodation into the ribosome (By similarity). The growing protein chain is subsequently transferred from the P-site peptidyl tRNA to the A-site aa-tRNA, extending it by one amino acid through ribosome- catalyzed peptide bond formation (By similarity). .
Each row is a cancer, strongest overall evidence first. The two dots show how strong the inherited (germline) and tumour-mutation (somatic) evidence is; the line between them is the gap.
Scores run from 0 (no evidence) to 1 (strongest). A missing dot at 0 means Open Targets holds no evidence of that kind. Source: Open Targets Platform, fetched live.
Tractability
- Small molecule
- Advanced Clinical
- PROTAC
- Database Ubiquitination, Half-life Data, Small Molecule Binder
gnomAD loss of function constraint: o/e 0.12728999555110931 (upper bound 0.267630010843277). Low values mean loss of function is poorly tolerated, a safety flag for inhibition.
Who runs trials of these drugs
Principal investigators and study chairs on 4 registry trials, updated in the last three years, of the most advanced drugs against EEF1A2 (plitidepsin), ranked by Phase 2+ trials. Live from ClinicalTrials.gov.
- José Felipe VaronaHospital Universitario HM Montepríncipe · 1 of 1 trials Phase 2+
- José Jimeno DoñaquePharmaMar · 1 of 1 trials Phase 2+
- Pablo Guisado-VascoQuironsalud · 1 of 1 trials Phase 2+
- Pedro LandeteFundación de Investigación Biomédica - Hospital Universitario de La Princesa · 1 of 1 trials Phase 2+
- Roger ParedesGermans Trias i Pujol Hospital · 1 of 1 trials Phase 2+
Registry trials of plitidepsin updated in the last three years, counted by the country group of their listed sites. A trial with sites in several groups counts in each; 2 of 4 have all sites in one country.
Site counts are not patients per country, and trials registered only outside ClinicalTrials.gov are not covered. Where sites are is a fact about the record, not a judgement of its quality. Europe is the EU and EEA, the UK and Switzerland. Source: ClinicalTrials.gov, fetched live.
7 trials of drugs against EEF1A2 were stopped early; 1 give no reason
Terminated, withdrawn and suspended interventional trials of plitidepsin, newest update first, live from ClinicalTrials.gov. Each reason is quoted exactly as the registry gives it; we do not sort reasons into safety, efficacy or business. Dates are the last registry update. Showing the 7 most recent of 7.
- terminated · 2025-02-21 · PharmaMar · Plitidepsin“Sponsor has decided to end the study prematurely based on significant difficulties in the recruitment of patients, despite the implementation of corrective measures that still failed to increase the accrual rate required for a feasible completion.”
- terminated · 2024-12-02 · PharmaMar · Plitidepsin“Significant difficulties in the recruitment of participants.”
- terminated · 2021-01-25 · Institut Bergonié · plitidepsinNo reason given
- terminated · 2020-12-02 · PharmaMar · plitidepsin“PharmaMar has decided to end this study due to the slow recruitment rate of the trial”
- terminated · 2020-11-24 · PharmaMar · Aplidin (plitidepsin)“Poor recruitment”
- terminated · 2020-10-14 · PharmaMar · plitidepsin“The main reason that motivated the study termination was the slow recruitment of the trial.”
- terminated · 2018-11-09 · PharmaMar · Plitidepsin plus Cytarabine“Poor recruitment”
Paediatric incentives and obligations for EEF1A2's drugs
For plitidepsin: what EMA and FDA publish about paediatric plans, orphan status and pediatric approvals, and how many registered studies take children. Each line is a yes, no or not published fact from the record linked under it; none of it is a forecast.
- FDA pediatric target list: no · EEF1A2 is not on the listRule: Target is on FDA's Pediatric Molecular Target List (relevant targets). Source: FDA Pediatric Molecular Target List (Listed as February 2026 on the FDA Pediatric Oncology page; the file served is 9.7.22_the_relevant_molecular_target_list.xlsx, whose Summary of Changes sheet is headed 'SEPTEMBER 2022 UPDATE' (footnote date 2022-09-01)), 2026-11-11
- EU paediatric investigation plan: yes · EMEA-000095-PIP02-21 (plitidepsin, Treatment of Coronavirus disease 2019 (COVID-19)): W: decision granting a waiver in all age groups for all conditions or indications, 3 Dec 2021Rule: An EMA PIP decision (agreement, modification or waiver) lists the drug as its active substance, exact name. Source: EMA EMEA-000095-PIP02-21, 2026-11-11
- EU orphan designation: yes · EU/3/10/838 withdrawn 23 Feb 2011: Treatment of post-essential thrombocythaemia myelofibrosis; EU/3/10/839 withdrawn 23 Feb 2011: Treatment of post-polycythaemia vera myelofibrosis; EU/3/10/837 withdrawn 23 Feb 2011: Treatment of primary myelofibrosis; EU/3/04/245 positive 16 Nov 2004: Treatment of multiple myelomaRule: An EU orphan designation lists the drug as its active substance (exact name) or belongs to a medicine that does; withdrawn and expired designations are listed with their status. Source: EMA data download (dated snapshot), 2026-11-11
- Authorised in the EU: no · Aplidin: application withdrawn, orphan medicineRule: An EMA medicine record lists the drug as its active substance or INN, exact name; national-only authorisations are not in this file. Source: EMA EPAR Aplidin, 2026-11-11
- FDA orphan designation: not published · FDA's orphan designation database turns away automated requests, so this app does not read it; search it by hand at the linkRule: Would be: an FDA orphan designation names the drug. Source: FDA orphan designations search
- FDA pediatric oncology approval: no · FDA's table lists no pediatric approval of plitidepsinRule: FDA's Pediatric Oncology Drug Approvals table names the drug. Source: FDA Pediatric Oncology Drug Approvals (content current as of 2026-03-03), 2026-11-12
- Registered studies open to children: no · No interventional study of plitidepsin includes patients under 18Rule: The registry's age group includes Child (birth to 17 years), which also counts studies that set no minimum age. Source: ClinicalTrials.gov search, 2026-11-12
Rare pediatric disease voucher. FDA, content current as of 29 Apr 2026: “As of February 3, 2026, enactment of the Consolidated Appropriations Act, 2026, the rare pediatric disease PRV program will sunset after September 30, 2029. FDA may not award any PRVs under this program after September 30, 2029.” Voucher sale prices are not shown here; they appear only as company-reported news. FDA: Rare Pediatric Disease Designation and Priority Review Voucher Programs
All 1 drugs and clinical candidates as a table
Each drug, stage and indication links to its Open Targets record, where the trials and approvals behind it are listed. Salt forms (for example a mesylate) are listed as Open Targets records them, as separate entries.
| Drug | Type | Highest stage | Indications | Source records |
|---|---|---|---|---|
| PLITIDEPSIN | Small molecule | approval | neoplasm, plasma cell myeloma, COVID-19, Immunoblastic Lymphadenopathy, prostate adenocarcinoma, non-Hodgkin lymphoma, myelofibrosis, dedifferentiated liposarcoma, +3 more | Open Targets · ChEMBL |